S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
Log in

Akari Therapeutics News Headlines (NASDAQ:AKTX)

$1.90
-0.03 (-1.55 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$1.86
Now: $1.90
$1.92
50-Day Range
$1.73
MA: $1.88
$2.06
52-Week Range
$1.56
Now: $1.90
$9.20
Volume228,856 shs
Average Volume1.03 million shs
Market Capitalization$30.13 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.8

Headlines

Akari Therapeutics (NASDAQ AKTX) News Headlines

Source:
DateHeadline
SKT, CLVS among premarket gainersSKT, CLVS among premarket gainers
seekingalpha.com - December 2 at 12:42 PM
Akari up 28% premarket on advancement of nomacopanAkari up 28% premarket on advancement of nomacopan
seekingalpha.com - December 2 at 12:42 PM
Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting  Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting  
finance.yahoo.com - December 2 at 12:42 PM
What Kind Of Shareholder Owns Most Akari Therapeutics, Plc (NASDAQ:AKTX) Stock?What Kind Of Shareholder Owns Most Akari Therapeutics, Plc (NASDAQ:AKTX) Stock?
finance.yahoo.com - November 18 at 9:07 AM
Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical ProgressAkari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress
www.benzinga.com - November 4 at 11:28 AM
Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical ProgressAkari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress
finance.yahoo.com - November 4 at 11:28 AM
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC TrialAkari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial
finance.yahoo.com - October 14 at 9:10 AM
Akaris Coversin shows positive effect in mid-stage pemphigoid studyAkari's Coversin shows positive effect in mid-stage pemphigoid study
seekingalpha.com - October 10 at 1:08 PM
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV CongressAkari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress
finance.yahoo.com - October 10 at 1:08 PM
How Much Cash Is Left In The Bank For Akari Therapeutics, Plc (NASDAQ:AKTX)?How Much Cash Is Left In The Bank For Akari Therapeutics, Plc (NASDAQ:AKTX)?
finance.yahoo.com - September 20 at 3:49 PM
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare ConferenceAkari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference
finance.yahoo.com - September 18 at 9:17 AM
Akaris Nomacopan Gets Orphan Drug Tag for Rare Skin DiseaseAkari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease
www.msn.com - September 16 at 9:36 PM
Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin DiseaseAkari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease
finance.yahoo.com - September 16 at 1:31 PM
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous PemphigoidAkari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
finance.yahoo.com - September 13 at 2:41 PM
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & MoreBiotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
finance.yahoo.com - September 4 at 11:47 AM
Akaris Nomacopan Gets Orphan Drug Tag for Rare DiseaseAkari's Nomacopan Gets Orphan Drug Tag for Rare Disease
www.nasdaq.com - September 3 at 10:22 AM
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early SeptemberAkari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September
finance.yahoo.com - September 3 at 10:22 AM
Akari's Nomacopan Gets Orphan Drug Tag for Rare DiseaseAkari's Nomacopan Gets Orphan Drug Tag for Rare Disease
finance.yahoo.com - September 2 at 10:01 AM
Akaris 2-Day Rally: What You Need To KnowAkari's 2-Day Rally: What You Need To Know
feeds.benzinga.com - August 30 at 11:57 AM
Akaris nomacopanan an Orphan Drug in U.S. for HSCT-TMA; shares up 15% premarketAkari's nomacopanan an Orphan Drug in U.S. for HSCT-TMA; shares up 15% premarket
seekingalpha.com - August 30 at 9:02 AM
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)
finance.yahoo.com - August 30 at 9:02 AM
Akari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopanAkari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopan
finance.yahoo.com - August 30 at 9:02 AM
Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical ProgressAkari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress
finance.yahoo.com - August 29 at 11:03 AM
26 Healthcare Stocks Moving In Thursdays Pre-Market Session26 Healthcare Stocks Moving In Thursday's Pre-Market Session
www.msn.com - August 15 at 11:06 PM
Good News for Stem Cell TransplantsGood News for Stem Cell Transplants
247wallst.com - August 14 at 6:25 PM
Akaris nomacopan Fast Trackd for HSCT-TMA; shares up 62% premarketAkari's nomacopan Fast Track'd for HSCT-TMA; shares up 62% premarket
seekingalpha.com - August 14 at 6:25 PM
Why Shares Of Micro-Cap Biotech Akari Therapeutics Are Ripping HigherWhy Shares Of Micro-Cap Biotech Akari Therapeutics Are Ripping Higher
www.benzinga.com - August 14 at 6:25 PM
Akari Therapeutics stock rockets on heavy volume after FDA grants nomacopan Fast Track designationAkari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation
www.marketwatch.com - August 14 at 6:25 PM
AKTX, WKHS among premarket gainersAKTX, WKHS among premarket gainers
seekingalpha.com - August 14 at 6:25 PM
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
finance.yahoo.com - August 14 at 8:36 AM
Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid diseaseAkari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease
finance.yahoo.com - August 9 at 8:50 AM
Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with BullousAkari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous
www.nasdaq.com - July 31 at 5:46 PM
Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019
finance.yahoo.com - July 31 at 5:46 PM
Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its VolatilityBefore You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility
finance.yahoo.com - July 17 at 5:22 PM
Alexion's Ultomiris Receives EU Approval for PNH in AdultsAlexion's Ultomiris Receives EU Approval for PNH in Adults
finance.yahoo.com - July 4 at 9:30 AM
Akari Therapeutics, Plc Announces $4.5 Million Registered Direct OfferingAkari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering
finance.yahoo.com - June 28 at 9:30 AM
Alexion's sBLA for Ultomiris Gets Priority Review From FDAAlexion's sBLA for Ultomiris Gets Priority Review From FDA
finance.yahoo.com - June 21 at 11:56 AM
Akaris Lead Candidate Found Safe, Effective In Treating Eye InflammationAkari's Lead Candidate Found Safe, Effective In Treating Eye Inflammation
finance.yahoo.com - June 19 at 6:24 PM
Akari +16% premarket on positive Nomacopan dataAkari +16% premarket on positive Nomacopan data
seekingalpha.com - June 19 at 12:05 PM
Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)
finance.yahoo.com - June 19 at 12:05 PM
Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical ProgressAkari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress
finance.yahoo.com - May 29 at 9:30 AM
FDA Events Put Healthcare Stocks In The Headlines: Heres One That No Ones Talking About YetFDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet
finance.yahoo.com - April 29 at 9:23 AM
Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4
www.nasdaq.com - April 26 at 9:28 AM
Akari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye DiseasesAkari Therapeutics Announces Expanded Ophthalmology Program Based on Positive Emerging Data on LTB4-C5 Dual Action in Surface and Back of the Eye Diseases
finance.yahoo.com - April 26 at 9:28 AM
Akari Makes Its Mark In Phase 2 Study Against Rare DiseaseAkari Makes Its Mark In Phase 2 Study Against Rare Disease
seekingalpha.com - April 25 at 9:31 AM
Mid-Afternoon Market Update: Dow Rises Over 100 Points; Akari Therapeutics Shares Spike HigherMid-Afternoon Market Update: Dow Rises Over 100 Points; Akari Therapeutics Shares Spike Higher
www.nasdaq.com - April 23 at 5:27 PM
Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business HighlightsAkari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights
finance.yahoo.com - April 23 at 5:27 PM
Microcap Biotech Akari Rallies On Coversin Trial ResultsMicrocap Biotech Akari Rallies On Coversin Trial Results
feeds.benzinga.com - April 23 at 12:16 PM
Akari up 25% premarket on positive Coversin data in rare skin disorderAkari up 25% premarket on positive Coversin data in rare skin disorder
seekingalpha.com - April 23 at 9:29 AM
Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous PemphigoidAkari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid
finance.yahoo.com - April 23 at 9:29 AM
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: What is a bull market?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel